Long noncoding RNA LINC00261 regulates endometrial carcinoma progression by modulating miRNA/FOXO1 expression

Abstract

LINC00261 is downregulated in endometrial carcinoma and associated with metastasis of this cancer. LINC00261 elevates FOXO1 protein levels through reducing FOXO1-targeted miRNAs to suppress endometrial carcinoma cell proliferation, migration, and invasion.

Development of a long non-coding RNA signature for prediction of response to neoadjuvant chemoradiotherapy in locally advanced rectal adenocarcinoma

“…Our findings show that not only lncRNAs are differentially expressed in a meaningful way in responder vs. non-responder patients, but also that such category of molecules is potentially able to stratify cases with surprisingly high accuracy. From our experiments, we indeed observed lncRNAs that have been independently associated with tumorigenesis, prognosis, and outcome in several tumor subtypes including colorectal cancer [25,26,27]. In particular, LINC00261 appears repeatedly in the scientific literature for its functional association with several neoplastic and proliferative disorders [33,34,35,36,37], and its identification as a highly differentially expressed molecule in LARC according to nCRT deserves special attention for its potential in translational research.…”

“…While many lncRNAs still miss a known role in cancer, we observed that several of the lncRNAs identified by our analysis have been independently described in association with neoplastic disorders. Of special interest, LINC00261 exhibited a 6.6-fold change between responders and non-responders (FDR = 0.0018, Fig 3A), and was recently described for its role in sensitization to chemotherapy in colorectal adenocarcinoma models [25], potential prognostic role in lung cancer [26], and progression regulation in endometrial carcinoma [27]. Moreover, LINC00324, with a fold-change = 3.6 (FDR = 0.0022, Fig 3B), and LINC00511 (fold-change = 1.81, FDR = 0.0196), have been characterized in comprehensive efforts to understand the functions of such molecules in cancer [28], potentially acting as bona fide oncogenes [29] Three lncRNAs exhibit great accuracy as a predictive signature for response nCRT…”

Peer Review #2 of "Comprehensive analysis of lncRNA-associated competing endogenous RNA network in tongue squamous cell carcinoma (v0.2)"

“…LINC00261 is a tumor suppressor positively associated with prognosis in many tumors, such as hepatocellular carcinoma (Zhang et al 2018a), endometrial carcinoma (Fang et al 2018) and nonsmall cell lung (Liu et al 2017). Its functions mainly include inhibiting tumor cell proliferation, invasion and metastasis.…”

Empty

“…The competing endogenous RNA (ceRNA) network including lncRNAs, microRNAs (miRNAs) and message RNAs (mRNAs) has been well-documented in cancers [17] including lung cancer [18]. Comprehensive analysis of LINC00261-associated ceRNA net has been announced in tongue squamous cell carcinoma and endometrial carcinoma [19,20]. However, the outcomes in this field remain disappointed, especially in lung cancer.…”

“…It is well-documented that LINC00261 exhibited anti-tumor role in different cancers, even though the investigations focused on LINC00261 remain very limited so far. LINC00261-associated ceRNA net has been gradually establishing including LINC00261/miR-132-3p/BCL2L11 in endometriosis [23], LINC00261/miR-558/TIMP4 in pre-eclampsia [24], LINC00261/miR-182, miR-183, miR-153, miR-27a, and miR-96/FOXO1 in endometrial carcinoma [20], and LINC00261/miR-19a/KLF2 in NSCLC ( Figure S3). More and further LINC00261/miRNAs/mRNAs pathways should be revealed in cancers such as lung cancer.…”